[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635578":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":30,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Belzutifan Group",null,"Subjects received Belzutifan",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"David Ka-Wai LEUNG, FRCS, MBChB","CONTACT","35053933","davidleung@surgery.cuhk.edu.hk",[19],{"facility":20,"status":10,"city":21,"state":10,"zip":10,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":10},"Prince of Wales Hospital","Shatin","Hong Kong","HK",{"type":25,"coordinates":26},"Point",[27,28],114.18333,22.38333,{"lat":28,"lon":27},{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","NG Chi Fai","Professor","100635578","belzutifan-vhl-rcc-hk-prospective-registry-100635578",false,"NCT07554508","Belzutifan VHL RCC HK Prospective Registry","A Prospective Registry for Belzutifan in the Treatment of Von Hippel-Lindau (VHL) Disease","Inclusion Criteria:\n\n* Adult patients (age 18 or above) with confirmed VHL-spectrum disease through clinical and\u002For genetic diagnosis.\n* The patient decided to use Belzutifan for their treatment.\n\nExclusion Criteria:\n\n* Tumour requiring immediate resection.\n* Pregnancy or unwillingness to use contraception if of childbearing potential.\n* Uncontrolled comorbidities (e.g., active infection, severe cardiopulmonary disease).","ALL","18 Years",{"count":44,"type":45},100,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the Belzutifan's efficacy, drug safety, disease course, and the health-economic impact of the treatment to Von Hippel-Lindau (VHL) syndrome.",[49],"VHL - Von Hippel-Lindau Syndrome","NOT_YET_RECRUITING","2026-04-29",{"date":53,"type":54},"2026-05-05","ACTUAL",{"date":56,"type":45},"2026-05",{"date":58,"type":45},"2029-03-31",{"name":5,"class":6},1]